{"entity":{"id":"da-biib080","kind":"drug","name":"Diranersen (BIIB080)","aka":[],"tldr":"BIIB080 is an investigational tau-lowering antisense medicine. It is not an approved dementia treatment.","summary":"Biogen’s intrathecal ASO programme targets tau RNA. Phase 2 safety and cognition outcomes are still being established. Not for self-administration.","status":"phase-2","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT05399888","url":"https://clinicaltrials.gov/study/NCT05399888"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease","mild-cognitive-impairment"],"sections":[],"technologies":[],"targets":["da-target-tau"],"drugs":[],"companies":["da-biogen"],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-biib080"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"BIIB080","modality":"ASO","mechanism":"Investigational antisense oligonucleotide aimed at reducing MAPT / tau expression.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/da-biib080/","neighbours":{"cancer":[{"id":"alzheimers-disease","kind":"cancer","name":"Alzheimer’s disease","route":"/diagnoses/alzheimers-disease/"},{"id":"mild-cognitive-impairment","kind":"cancer","name":"Mild cognitive impairment","route":"/diagnoses/mild-cognitive-impairment/"}],"target":[{"id":"da-target-tau","kind":"target","name":"Tau","route":"/targets/da-target-tau/"}],"company":[{"id":"da-biogen","kind":"company","name":"Biogen","route":"/companies/da-biogen/"}],"trial":[{"id":"da-trial-biib080","kind":"trial","name":"Diranersen / BIIB080 Phase 2","route":"/trials/da-trial-biib080/"}],"technology":[{"id":"da-tech-tau-therapeutics","kind":"technology","name":"Tau-directed therapeutics","route":"/technologies/da-tech-tau-therapeutics/"}]}}